Human monoclonal nicotine specific antibodies

1. An isolated monoclonal antibody specifically binding nicotine, wherein said monoclonal antibody is a human monoclonal antibody, and

(a) wherein said monoclonal antibody comprises at least one heavy chain variable region (HCVR), wherein said HCVR comprises:

(i) one heavy chain complementarity determining region (HC CDR)1, wherein said HC CDR1 comprises the peptide of SEQ ID NO:1;

(ii) one HC CDR2, wherein said HC CDR2 comprises the peptide of SEQ ID NO:2; and

(iii) one HC CDR3, wherein said HC CDR3 comprises the peptide of any one of SEQ ID NOs 3 and 4; and

(b) wherein said monoclonal antibody comprises at least one light chain variable region (LCVR), wherein said LCVR comprises:

(i) one light chain complementarity determining region (LC CDR)1, wherein said LC CDR1 comprises the peptide of any one of SEQ ID NOs 5, 6, and 7;

(ii) one LC CDR2, wherein said LC CDR2 comprises the peptide of SEQ ID NO:8;

(iii) one LC CDR3, wherein said LC CDR3 comprises the peptide of any one of SEQ ID NOs 9 and 10.

2. The monoclonal antibody of claim 1 , wherein:

(a) said HCVR comprises a peptide selected from SEQ ID NOs 24, 28, 33, and 39; and

(b) wherein said LCVR comprises a peptide selected from SEQ ID NOs 26, 31, 35, 37, and 41.

3. The monoclonal antibody of claim 1 , wherein:

(a) said HCVR comprises the peptide of SEQ ID NO:24, and wherein said LCVR comprises the peptide of SEQ ID NO:26;

(b) said HCVR comprises the peptide of SEQ ID NO:28, and wherein said LCVR comprises the peptide of SEQ ID NO:31;

(c) said HCVR comprises the peptide of SEQ ID NO:33, and wherein said LCVR comprises the peptide of SEQ ID NO:35;

(d) said HCVR comprises the peptide of SEQ ID NO:28, and wherein said LCVR comprises the peptide of SEQ ID NO:37; or

(e) said HCVR comprises the peptide of SEQ ID NO:39, and wherein said LCVR comprises the peptide of SEQ ID NO:41.

4. The monoclonal antibody of claim 1 , wherein said monoclonal antibody comprises at least one gamma 2 heavy chain and at least one lambda light chain, wherein

(a) said gamma 2 heavy chain comprises the peptide of SEQ ID NO:73, and wherein said lambda light chain comprises the peptide of SEQ ID NO:74;

(b) said gamma 2 heavy chain comprises the peptide of SEQ ID NO:75, and wherein said lambda light chain comprises the peptide of SEQ ID NO:76;

(c) said gamma 2 heavy chain comprises the peptide of SEQ ID NO:77, and wherein said lambda light chain comprises the peptide of SEQ ID NO:78;

(d) said gamma 2 heavy chain comprises the peptide of SEQ ID NO:75, and wherein said lambda light chain comprises the peptide of SEQ ID NO:79; or

(e) said gamma 2 heavy chain comprises the peptide of SEQ ID NO:80, and wherein said lambda light chain comprises the peptide of SEQ ID NO:81.

5. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is an IgG2.

6. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is specifically binding (S)-(−)-nicotine and (R)-(+)-nicotine.

7. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is binding (S)-(−)-nicotine and (R)-(+)-nicotine, wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (S)-(−)-nicotine is 1 to 100 nM.

8. The monoclonal antibody of claim 1 , wherein HC CDR 3 comprises the peptide of SEQ ID NO:3, and wherein said LC CDR1 comprises the peptide of SEQ ID NO:5, and wherein said LC CDR3 comprises the peptide of SEQ ID NO:9.

9. The monoclonal antibody of claim 2 , wherein said HCVR comprises the peptide of SEQ ID NO:24, or wherein said LCVR comprises the peptide of SEQ ID NO:26.

10. The monoclonal antibody of claim 1 , wherein said HCVR comprises the peptide of SEQ ID NO:24, and wherein said LCVR comprises the peptide of SEQ ID NO:26.

11. The monoclonal antibody of claim 1 , wherein said monoclonal antibody comprises at least one gamma 2 heavy chain and at least one lambda light chain, wherein said gamma 2 heavy chain comprises the peptide of SEQ ID NO:73, and wherein said lambda light chain comprises the peptide of SEQ ID NO:74.

12. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is a human monoclonal antibody, and wherein said monoclonal antibody is binding (S)-(−)-nicotine and (R)-(+)-nicotine, wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (S)-(−)-nicotine is 0.1 to 10 nM; and wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (R)-(+)-nicotine is 0.1 to 10 nM; and wherein said monoclonal antibody comprises a gamma 2 heavy chain and a lambda light chain, wherein said gamma 2 heavy chain comprises the peptide of SEQ ID NO:73, and wherein said lambda light chain comprises the peptide of SEQ ID NO:74.

13. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is a human monoclonal antibody, and wherein said monoclonal antibody is binding (S)-(−)-nicotine and (R)-(+)-nicotine, wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (S)-(−)-nicotine is 10 to 100 nM; and wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (R)-(+)-nicotine is 0.1 to 10 nM; and wherein said monoclonal antibody comprises a gamma 2 heavy chain and a lambda light chain, wherein said gamma 2 heavy chain comprises the peptide of SEQ ID NO:75, and wherein said lambda light chain comprises the peptide of SEQ ID NO:76.

14. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is a human monoclonal antibody, and wherein said monoclonal antibody is binding (S)-(−)-nicotine and (R)-(+)-nicotine, wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (S)-(−)-nicotine is 10 to 100 nM, and wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (R)-(+)-nicotine is 1 to 20 nM; and wherein said monoclonal antibody comprises a gamma 2 heavy chain and a lambda light chain, wherein said gamma 2 heavy chain comprises the peptide of SEQ ID NO:77, and wherein said lambda light chain comprises the peptide of SEQ ID NO:78.

15. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is a human monoclonal antibody, and wherein said monoclonal antibody is binding (S)-(−)-nicotine and (R)-(+)-nicotine, wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (S)-(−)-nicotine is 20 to 60 nM; and wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (R)-(+)-nicotine is 0.1 to 10 nM; wherein said monoclonal antibody comprises a gamma 2 heavy chain and a lambda light chain, wherein said gamma 2 heavy chain comprises the peptide of SEQ ID NO:75, and wherein said lambda light chain comprises the peptide of SEQ ID NO:79.

16. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is a human monoclonal antibody, and wherein said monoclonal antibody is binding (S)-(−)-nicotine and (R)-(+)-nicotine, wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (S)-(−)-nicotine is 20 to 80 nM; and wherein the dissociation constant Kd of said binding of said monoclonal antibody to said (R)-(+)-nicotine is 0.1 to 15 nM; wherein said monoclonal antibody comprises a gamma 2 heavy chain and a lambda light chain, wherein said gamma 2 heavy chain comprises the peptide of SEQ ID NO:80, and wherein said lambda light chain comprises the peptide of SEQ ID NO:81.

17. A method of passive immunization against nicotine, said method comprising administering to a subject an effective amount of the monoclonal antibody of claim 1 .

18. The method of claim 17 , wherein said subject is a human.

19. A method of treating of nicotine addiction, said method comprising administering to a subject an effective amount of the monoclonal antibody of claim 1 .

20. The method of claim 19 , wherein said subject is a human.